Navigation Links
Trigemina to Present at the 2013 BIO International Convention
Date:4/22/2013

MORAGA, Calif., April 22, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans , Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, will be presenting at the 2013 BIO International Convention's BIO Business Forum on April 22nd, 2013 at the McCormick Place in Chicago, Illinois.

Dr. Yeomans will be providing an overview of Trigemina's lead product candidate, TI-001, an intranasal oxytocin therapy for the treatment of chronic and subacute head pain, and the therapy's patented mechanism of action as it correlates to its overall safety and efficacy. TI-001, which is being evaluated in a Phase 2 clinical study starting patient enrollment in April 2013, has shown promising preclinical and preliminary study results for use as a safe, non-narcotic form of therapy for the effective relief of chronic migraine.

Event:  BIO International Convention's BIO Business Forum
Date:  Monday, April 22nd, 2013
Place:  Chicago Cubs Room at the McCormick Place
Time:  2:00 pm CT

About Trigemina

Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.

For additional information, please visit www.trigemina.com

About the BIO International Convention

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org

Contact:

The Ruth Group
Aaron Estrada (media)
aestrada@theruthgroup.com  
(646) 536-7028

Trigemina
Charles Yeomans
cyeomans@trigemina.com 
(925) 377-0664

 


'/>"/>
SOURCE Trigemina, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
2. Cambridge Semantics to Present the Case for Unified Information Access at Enterprise Data World 2013
3. Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
4. VentriNova, Inc. to present at TEDMED 2013
5. Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
6. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
8. TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
9. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
10. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
11. New Bed Bug Bill Submitted and Complimentary Samples of Non-Pesticide Bed Bug Spray Presented to Help Landlords and Tenants, My Cleaning Products Shares the Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... Korean researchers ... that it may offer a new way to treat the disease. Surviving Mesothelioma has ... now. , Scientists from several Korean institutions based their mesothelioma study on the ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):